Compile Data Set for Download or QSAR
Report error Found 150 of ic50 data for polymerid = 1200
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM112499(DACOMITINIB | US8623883, No. 2 | WO2022090481, Exa...)
Affinity DataIC50: 0.0100nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022090481
PDB3D3D Structure (crystal)
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM50322823((S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahy...)
Affinity DataIC50: 0.0200nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022090481
PDB3D3D Structure (crystal)
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538119(US11253516, Example 21)
Affinity DataIC50: 0.100nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700922(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6-methyl...)
Affinity DataIC50: 0.100nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538123(US11253516, Example 25)
Affinity DataIC50: 0.200nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538125(US11253516, Example 27)
Affinity DataIC50: 0.300nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538120(US11253516, Example 22)
Affinity DataIC50: 0.400nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM50029668(AZD-9291 | Osimertinib | US10085983, Compound AZD-...)
Affinity DataIC50: 0.5nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
In DepthDetails
WIPO WO2022090481

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538108(US11253516, Example 10)
Affinity DataIC50: 0.700nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538117(US11253516, Example 19)
Affinity DataIC50: 0.700nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM538126(US11253516, Example 28)
Affinity DataIC50: 0.900nMAssay Description:The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700794(2,5-dichloro-N-(2- nitrophenyl)pyrimidin-4-amine |...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700796(N1-(2,5-dichloropyrimidin-4- yl)benzen-1,2-diamine...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700843(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)pr...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700865(tert-butyl (4-fluoro-2-methoxy-5- nitrophenyl)carb...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700878(tert-butyl (4-((2- (dimethylamino)ethyl)(methyl) a...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700880(tert-butyl (5-acrylamido-4-((2- (dimethylamino)eth...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700883(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-4...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700884(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)et...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700885(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)pr...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700887(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)benzen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700889(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)propan...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700891(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)ethane...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700892(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700894(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino)phen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700895(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700896(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino)phen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700897(N-(2-((2-chloro-5-methylpyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700898(N-(2-((2-chloro-5-methylpyrimidin- 4-yl)amino)phen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700901(N-(2-((2-chloro-5-methylpyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700902(N-(5-amino-4-methoxy-2- (methyl(2-(pyrrolidin-1- y...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700903(N-(5-amino-4-methoxy-2-(2- (pyrrolidin-1- yl)ethox...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700904(N-(5-amino-4-methoxy-2- (methyl(2-(piperidin-1- yl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700905(benzyl (2-((2-acrylamido-4-amino- 5-methoxyphenyl)...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700906(benzyl (2-((2-acrylamido-4-((5- chloro-4-((2- (met...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700907(benzyl (2-((2-acrylamido-4-amino- 5- methoxyphenyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700908(benzyl (2-((2-acrylamido-4-((5- chloro-4-((2- (met...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700909(N-(2-((2-((5-amino-2-methoxy-4- morpholinophenyl)a...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700910(N-(2-((2-((5-amino-2-methoxy-4- (4-methylpiperazin...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700911(N-(2-((2-((5-amino-4-((2- (dimethylamino)ethyl)(me...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700912(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-N...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700913(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-N...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700914(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-N...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700915(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-N...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700916(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-N...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700917(N-(2-chloro-6-((2,5- dichloropyrimidin-4- yl)amino...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700918(N-(2-chloro-6-((2,5- dichloropyrimidin-4- yl)amino...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700919(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6- methy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700920(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6-isopro...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM700923(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6- ethyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

Displayed 1 to 50 (of 150 total ) | Next | Last >>
Jump to: